Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.54 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.54 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.54 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513023 | 0.86 | TRPM8 (0.46) | TRPM8GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL1359576 | 0.84 | GABBR2 (0.52) | TRPM8GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL2487026 | 0.83 | TRPM8 (0.41) | TRPM8 | |
| SCHEMBL2171447 | 0.82 | TRPM8 (0.39) | TRPM8GABBR2GABBR1GABRR1 | |
| SCHEMBL2172020 | 0.81 | GABBR2 (0.48) | TRPM8GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL2353740 | 0.80 | GABBR2 (0.59) | GABBR2GABBR1GABRR1 | |
| SCHEMBL5085512 | 0.80 | GABBR2 (0.39) | TRPM8GABBR2GABBR1GABRR1 | |
| SCHEMBL497185 | 0.80 | GABBR2 (0.76) | TRPM8GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL2352929 | 0.79 | GABBR2 (0.57) | TRPM8GABBR2GABBR1GABRR1LPAR3 | |
| SCHEMBL339782 | 0.79 | GABBR2 (0.47) | TRPM8GABBR2GABBR1GABRR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379571-A1 | METHOD FOR THE PRODUCTION OF MIXED-SUBSTITUTED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010069419-A1 | METHOD FOR THE PRODUCTION OF MIXED-SUBSTITUTED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | HAO2, ACSL3, SCO2 | TRPM8 4064/4885GABBR2 3092/4885GABBR1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.